MDT

88.01

+0.07%↑

A

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

A

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

A

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

A

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

A

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Search

Teva Pharmaceutical Industries Ltd.

Закрыт

СекторЗдравоохранение

31.73 2.06

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

31.15

Макс.

31.94

Ключевые показатели

By Trading Economics

Доход

47M

481M

Продажи

231M

4.7B

P/E

Средняя по отрасли

24.645

66.418

Рентабельность продаж

10.21

Сотрудники

31,173

EBITDA

-474M

632M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+28.39% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-1.3B

36B

Предыдущая цена открытия

29.67

Предыдущая цена закрытия

31.73

Техническая оценка

By Trading Central

Уверенность

Weak Bullish Evidence

Teva Pharmaceutical Industries Ltd. График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

9 окт. 2025 г., 09:10 UTC

Популярные акции

Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials -- WSJ

7 мая 2025 г., 17:01 UTC

Главные новости

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

Сравнение c конкурентами

Изменение цены

Teva Pharmaceutical Industries Ltd. Прогноз

Целевая цена

By TipRanks

28.39% рост

Прогноз на 12 месяцев

Средняя 39.57 USD  28.39%

Максимум 45 USD

Минимум 35 USD

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для Teva Pharmaceutical Industries Ltd. на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

8 ratings

8

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

15.58 / N/AПоддержка и Сопротивление

Краткосрочная

Weak Bullish Evidence

Среднесрочная

Strong Bullish Evidence

Долгосрочная

Bullish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
help-icon Live chat